The Effects of Dexlansoprazole for the Treatment of Throat-Related Reflux

Status Terminated

Clinical Trial Summary

Recent studies have demonstrated that patients with throat-related reflux often require twice daily proton pump inhibitor therapy to attain significant symptomatic improvement, with once daily therapy offering little relief. As dexlansoprazole is a twice-daily release proton pump inhibitor requiring only once-daily dosing, it may provide laryngopharyngeal reflux (LPR) symptomatic relief comparable to that of twice daily dosing, yet be more readily approved by third party payers because of its once daily dosing requirements. It is hypothesized that, in patients with pharyngeal-probe proven throat reflux, there will be significantly greater improvement in symptoms and pharyngeal probe findings in those patients receiving dexlansoprazole than those receiving placebo alone.

Clinical Trial Description

The aim of the study is to compare outcomes, based on RSI-based symptomatic improvement and pharyngeal probe results, after LPR patients are treated for two months with once-daily (QAM) Kapidex versus placebo.Forty patients with pharyngeal pH probe-documented LPR and an elevated reflux symptom index (RSI) (≥14) will be enrolled into a double-blinded placebo controlled study. Twenty patients will receive Kapidex once daily, while twenty receive placebo. Patients will return at two months for evaluation with repeat RSI documentation and repeat pharyngeal pH probe testing. Student t-test will be used to determine if the change in RSI and pH-probe results differs between the study and placebo group. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01317472
Study type	Interventional
Source	Indiana University
Contact
Status	Terminated
Phase	N/A
Start date	March 2011
Completion date	November 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06205446` - Application of Diaphragmatic Breathing in Patients With Disorders of Gut-brain Interaction	N/A
Completed	`NCT02552966` - Assessing the Impacts of a UESAD on Laryngeal Symptoms and Salivary Pepsin	N/A
Completed	`NCT01450748` - Efficacy and Safety of Alginos Oral Suspension to Treat Laryngopharyngeal Reflux	Phase 3
Recruiting	`NCT04827355` - Reflux Band in Laryngopharyngeal Reflux	N/A
Not yet recruiting	`NCT03455803` - Effect of CPAP Therapy on LPR Among Patients With OSAS	N/A
Withdrawn	`NCT02530879` - Comparison of Voice Therapy and Antireflex Therapy in LPR	Phase 4
Completed	`NCT01854970` - Benefit of Pharyngeal and Oesophageal pH-impedance of Patients With High Suspicion of Laryngopharyngeal Reflux	N/A
Completed	`NCT00321503` - Study of an Oropharyngeal Aerosolized pH Probe for Diagnosing Laryngopharyngeal Reflux (LPR)	N/A
Completed	`NCT01880892` - Laryngopharyngeal Reflux Before and After Cricopharyngeal Myotomy	N/A
Completed	`NCT02183961` - Three Methods Used in the Diagnosis of EER in Children With OME	N/A
Not yet recruiting	`NCT01328652` - Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy	Phase 4
Not yet recruiting	`NCT04383262` - Lexiva for the Treatment of LPR	Phase 3
Recruiting	`NCT04984304` - Individualized Diagnosis and Treatment of Extraesophageal Reflux in Patients With Chronic Cough	N/A
Withdrawn	`NCT03463395` - Efficacy of Reza Band for the Treatment of Laryngopharyngeal Reflux	N/A
Completed	`NCT00864396` - Twice Daily Prevacid for the Treatment of Laryngopharyngeal Reflux	Phase 1
Completed	`NCT03619811` - Precision Approach to PPI Therapy in Gastroesophageal Reflux Disease	N/A
Recruiting	`NCT05879029` - Clinical Study of Jinsang Liyan Capsules Combined With PPI in the Treatment of LPRD	Phase 4
Recruiting	`NCT05204303` - LPR Fluorescence Pilot
Terminated	`NCT01777854` - Anti-reflux Control to Decrease Post Tonsillectomy Pain	Phase 4
Withdrawn	`NCT01308502` - A New Nasopharyngeal pH Probe for Diagnosis of Laryngopharyngeal Reflux	Phase 4